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Abstract
Somatostatin receptor subtype 5 (SST5) is an emerging biomarker and actionable target in pituitary 
(PitNETs) and pancreatic (PanNETs) neuroendocrine tumors. Transcriptional and epigenetic regulation of 
SSTR5 gene expression and mRNA biogenesis is poorly understood. Recently, an overlapping natural 
antisense transcript, SSTR5-AS1, potentially regulating SSTR5 expression, was identified. We aimed to 
elucidate whether epigenetic processes contribute to the regulation of SSTR5 expression in PitNETs 
(somatotropinomas) and PanNETs. We analyzed the SSTR5/SSTR5-AS1 human locus in silico to identify 
CpG islands. SSTR5 and SSTR5-AS1 expression was assessed by quantitative real-time PCR (qPCR) in 27 
somatotropinomas, 11 normal pituitaries (NPs), and 15 PanNETs/paired adjacent (control) samples. We 
evaluated methylation grade in four CpG islands in the SSTR5/SSTR5-AS1 genes. Results revealed that 
SSTR5 and SSTR5-AS1 were directly correlated in NP, somatotropinoma and PanNET samples. 
Interestingly, selected CpG islands were differentially methylated in somatotropinomas compared with 
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features, and influenced pasireotide response. These results provide evidence that SSTR5 expression in 
PitNETs and PanNETs can be epigenetically regulated by the SSTR5-AS1 antisense transcript and, 
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1. Introduction
Neuroendocrine tumors (NETs) comprise a heterogeneous group of neoplasms, with rising incidence 
over the last decades [1-3]. These tumors arise from cells of (neuro)endocrine origin, which share common 
features like the synthesis, storage and secretion of hormones and neurotransmitters. NETs can be widely 
distributed throughout the body, although, they are more abundant in the gastrointestinal and respiratory 
tracts [1-3]. Specifically, pancreatic NETs (PanNETs), which display one of the highest increases in 
incidence within the different types of NETs in the last ten years [4], are associated to the endocrine 
compartment of the pancreas. In fact, PanNETs have been classically thought to be derived from hormone-
producing cells of the pancreatic Langerhans’ islets [5], although recent evidence has arisen challenging 
this concept, and it is presently under debate whether NETs can in fact be originated from a common cell 
progenitor from the pancreas [6]. Genetic alterations contributing to PanNETs tumorigenesis include 
frequent mutations in MEN1, ATRX or DAXX genes [7].
Additionally, tumors derived from the anterior pituitary have been classically termed adenomas due to 
their non-metastatic behavior [8]. However, based on their potential aggressiveness and associated 
morbimortality, the International Pituitary Pathology Club recently proposed to reclassify this pathology 
and to name them as pituitary neuroendocrine tumors or PitNETs [9], although some controversies have 
arisen for this nomenclature [10, 11]. Autopsy and imaging studies reveal that PitNETs are the most 
common intracranial neoplasms (prevalence 10-22 %, [12]. PitNETs are primarily classified according to 
their size and accompanying hormonal hypersecretion [8]. Among them, somatotropinomas arise from 
somatotropes and oversecrete growth hormone (GH), causing gigantism (in children/adolescents) or 
acromegaly, characterized by extremity enlargement, facial and skeletal changes, and metabolic, 
gastrointestinal, cardiovascular and respiratory complications [13, 14].
A common feature shared by most NETs is the key role played by somatostatin and its receptors 
(SST1-SST5) in their pathophysiological regulation and medical treatment, which is particularly relevant in 
PitNETs and PanNETs [13-17]. Indeed, somatostatin represents the main inhibitory signal for normal 
somatotropes and endocrine pancreatic cells, where it decreases hormone secretion [16, 18, 19]. 
Importantly, somatostatin also acts on tumor cells inhibiting hormone hypersecretion and cell proliferation, 
as reported in different tumor types including somatotropinomas, PanNETs and thyrotropinomas, which 
abundantly express SSTs [13-17]. In general, SST2 is the most expressed receptor in tumors, followed by 
SST5, with high tumor specificity [20]. Of note, the truncated SST5 splicing variant, SST5TMD4, has also 
been found to be notably expressed in several endocrine-related tumors, particularly PitNETs and PanNETs 
[21, 22]. Therein, SST5TMD4 has been associated with tumorigenesis and malignancy features, likely by 
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interplay of SST2 and SST5 is particularly important given their key role in the NETs response to treatment 
with synthetic somatostatin analogues (SSAs) such as octreotide, lanreotide or pasireotide [2].
First generation SSAs (octreotide and lanreotide) preferentially target SST2, with less affinity to 
SST5 —and, octreotide, SST3— and negligible binding for the other SSTs. These drugs have been widely 
used in the treatment of GH- and TSH-secreting PitNETs and also in PanNETs, to reduce hormonal 
secretion, control tumor volume and improve patient symptoms [26-28]. Nonetheless, a substantial 
proportion of patients are or become resistant to these treatments [29, 30]. Consequently, a second 
generation of SSAs with multireceptor binding affinity was developed, based on the idea that simultaneous 
targeting of several SST, like natural somatostatin, could improve effectiveness in unresponsive patients. 
From this group, the most widely used compound is pasireotide, showing high affinity to SST5, SST2, SST3 
and SST1 [31, 32]. However, SSAs actions do not only depend on their differential binding to specific 
SSTs. Actually, in somatotropinomas, although the complete set of factors defining SSA responsiveness is 
not yet fully defined, various specific tumor features and molecular markers have been shown to relevantly 
influence tumor response to SSAs, including granulation pattern, AIP and GNAS mutations, β-arrestin, 
filamin A and E-cadherin expression, as well as, interestingly, SSTR2/SSTR5 expression balance and 
SST5TMD4 presence [13, 16, 33, 34]. Thus, it is important to understand the mechanisms governing the 
expression of the SSTR5 gene and its resultant receptor variants (SST5, SST5TMD4, SST5TMD5), for they 
may impact NETs response to SSAs.
Gene expression is known to be regulated by multiple factors, among which extrinsic factors, such 
as epigenetic mechanisms, have gained great attention in recent years. A prime epigenetic modification is 
DNA methylation, which is based on the addition of a methyl group to a cytosine preceding a guanine 
(CpG). CpG residues are enriched at CpG islands, regions of the genome frequently associated with 
promoter function. Likewise, noncoding RNAs may act as modular epigenetic regulators [35]. A particular 
type of noncoding RNAs comprise natural antisense transcripts (NATs) [36], i.e. transcripts derived from 
the opposite strand to a protein-coding or sense gene, which can regulate the transcription of their 
corresponding sense genes. NATs importance is rising as sequencing technologies improve, and recent 
studies are deciphering NATs role in different diseases, including PitNETs [37], where they play distinct 
roles, like AFAP1-AS1, which influences tumor growth; or C5orf66-AS1, related to invasiveness. Recently,  
a NAT for SSTR5 was reported to be expressed in laryngeal squamous cell carcinoma, where it may act as 
tumor suppressor [38]. Nevertheless, its role in PitNETs and PanNETs has not been explored yet. 
Consequently, in this study we aimed to widen our still limited knowledge of the epigenetic 










Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & 
Sons Ltd.
PanNETs, and to explore the functional and pathological implications of those epigenetic underpinnings in 
tumor behavior to better understand the role of this receptor.
2. Material and methods
2.1 Patients and samples
This study was carried out within a project approved by the Research Ethics Committee of Córdoba 
(Comité de Ética de la Investigación de Córdoba) and was conducted in accordance with ethical standards 
of the Helsinki Declaration of the World Medical Association. Written informed consent was obtained from 
each patient. Pituitary samples were collected during transsphenoidal surgery from 27 acromegaly patients 
and 11 normal pituitaries (NPs) by autopsy from donors and were stored frozen. Formalin fixed paraffin-
embedded samples (FFPE, n = 15) were obtained from primary PanNETs; non-tumor adjacent tissue, used 
as control, was extracted from the same piece and both tissues were separated by expert pathologists 
(patient features summarized in Supplemental Table 1).
2.2 Cell culture and treatment
Functional assays were performed in PanNET model cell lines BON-1 and QGP-1 [39-42], using 
passages lower than 25 in all cases. BON-1 cells were kindly provided by Dr. M.C. Zatelli and were 
cultured in DMEM-F12 (Life Technologies, Barcelona, Spain), whereas QGP-1 cells were kindly provided 
by Dr. K. Öberg and were cultured in RPMI-1640 (Life Technologies), both supplemented with 10 % fetal 
bovine serum (FBS; Sigma-Aldrich, Madrid, Spain) and 0.2 % antibiotic (Gentamicin/Amphotericin B; 
Life Technologies). Cell lines were grown at 37 ˚C, in a humidified atmosphere with 5.0 % CO2 and were 
verified for mycoplasma contamination by PCR with specific mycoplasma primers. To ensure the identity 
of the cells, we could not employ typical STR tests, as they are not available for these cell lines. Therefore, 
we use a different strategy, by measuring an ample set of genes typically expressed by the cell lines as 
previously reported [39, 40], including SSTs, and secretory products (e.g., chromogranin, serotonin, or 
somatostatin). In addition, we have tested cell responses and behaviors after classic treatments which 
closely resembled those described by original studies [41, 42]. Pasireotide was provided by Novartis and 
administered at 100 nM, dissolved in sterile water, as previously reported [31, 43], and 5-azacytidine 
(Sigma-Aldrich) was administered at different doses, based on the literature [44], also dissolved in sterile 
water.
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BON-1 and QGP-1 cells were transfected with a specific shRNA targeting SSTR5-AS1, previously 
validated in our laboratory (Origene, Rockville, MD, USA), and selected with puromycin. On the other 
hand, SSTR5 was transiently silenced with a specific siRNA (Thermo Fisher). Specifically, cells were 
seeded in 6-wells culture plates and transfected with 1 μg of the small RNA, using Lipofectamine 2000 and 
Lipofectamine RNAiMAX Transfection Reagents (Thermo Fisher) for the shRNA and siRNA, 
respectively, during 6 h. Scramble shRNA/siRNA served as control.
2.4 DNA and RNA isolation and retrotranscription
Total RNA from cell lines was isolated using TRIzol Reagent (Sigma-Aldrich) treated with DNase 
(Promega, Barcelona, Spain). In FFPE samples, RNA was isolated RNeasy FFPE Kit (Qiagen, Limburg, 
Netherlands). Particularly genomic DNA and RNA from fresh pituitary samples were extracted using 
AllPrep DNA/RNA/Protein Kit (Qiagen). Nucleic acids amount and quality was determined using 
NanoDrop2000 spectrophotometer (Thermo Fisher) and reversely transcribed using random hexamer 
primers with the First Strand Synthesis Kit (Thermo Fisher).
2.5 Quantitative real time PCR (qPCR)
qPCR reactions were performed using Mx3000p system with the Brilliant III SYBR Green Master 
Mix (Stratagene, La Jolla, CA, USA) with specific primers (Supplemental Table 2a) [45]. Results were 
validated as previously reported [46], adjusting gene expression with a normalization factor, calculated 
from values of ACTB, GAPDH, HPRT1 and/or RNA18S1 control genes.
2.6 Methylation assay
DNA methylation of CpG islands overlapping SSTR5 and SSTR5-AS1 were evaluated in the 
PitNETs and normal pituitary cohort, as well as BON-1 and QGP-1 cell lines. One µg genomic DNA was 
used following a protocol previously reported [47] using EZ DNA methylation-Gold kit (Zymo, Irving, 
CA, USA). Primers were designed using PyroMark software (Qiagen; Supplemental Table 2b) for 300 bp 
amplicons, approximately. These primers included Illumina sequencing adaptors, used for a second–round 
PCR, which was then performed to index each pituitary sample. Samples were pooled, purified and size 
selected with AmpPure beads (Beckman-Coulter) and sequenced using the Illumina MiSeq v2 300 cycle 
run kit. Paired-end reads were mapped using Bismark to a custom genome made up of the amplicon 
sequences. An R script was then used to extract average methylation values for each CpG position. 
Methylation levels from multiple CpGs were then averaged to produce a value per amplicon, excluding 
positions where mutations/deletions at CpGs were frequently observed in patients; specifically, the first 
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2.7 Proliferation, colony formation and migration
Proliferation, colony formation and cell migration assays were performed as previously described 
[45, 48]. Briefly, BON-1 proliferation and colony formation were performed by seeding 1000 cells in 6-
wells plates for 10 days. For proliferation, cells were treated 24 h after seeding and refreshed every 48 h; 
for colony formation, treatment was made only during 24 h prior to seeding. QGP-1 proliferation assay was 
performed using Alamar-Blue Reagent (Bio-Source International, Camarillo, CA), as previously reported 
[45]. Cell migration was evaluated by wound-healing assay, seeding cells in 24-wells plates until maximum 
confluence. Then, we made a scratch in the middle on the well and took images of the scratch at 0 and 24 h. 
Wound healing was calculated as the uncovered area 24 hours after the wound compared to the uncovered 
area just after wounding. Wound-healing assay is not feasible in QGP-1 cell line since these cells grow in 
clusters and do not migrate to fill out the empty space made on the plate surface.
2.8 Western Blot
BON-1 and QGP-1 cells transfected and treated were lysed to analyze protein phosphorylation by 
western blot, following standard procedures [49], and using phospho-ERK (#4370S, Cell Signaling, 
Beverly, MA, USA), phospho-AKT (#4060S, Cell Signaling), AKT (#9272S, Cell Signaling), and ERK 
(sc-154, Santa Cruz Biotechnology, Dallas, TX, USA)  antibodies and HRP-conjugated goat-anti rabbit 
(#7074s; Cell Signaling) secondary antibody. Primary antibodies were diluted 1:1000 and secondary 
antibody was used at 1:2000. Band densitometry analysis was performed with ImageJ software, using total 
protein as reference factor of corresponding phosphorylated protein.
2.9 Statistical analyses
Statistical comparisons between groups were performed by unpaired parametric t-test and non-
parametric Mann-Whitney U test, according to normality (Kolmogorov-Smirnov test). Pearson’s or 
Spearman’s bivariate correlations were performed for quantitative variables. One-way ANOVA analysis 
was used for the statistical comparison between more than two groups, since all of them were normally 
distributed (Kolmogorov-Smirnov or Shapiro-Wilk tests). The p-values were two-sided and statistical 
significance was considered when p < 0.05. Statistical analyses were assessed using GraphPad Prism 7 
(GraphPad Software, La Jolla, CA, USA).
3. Results
3.1 Role of DNA methylation and natural antisense transcript (NAT) in the regulation of SSTR5 
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As an initial approach, we performed an in silico study of the structure of the SSTR5 gene (Figure 1A, 
Supplemental Figure 1). The information obtained from the UCSC Genome Browser (version 
GRCh37/hg19) revealed the existence of an overlapping gene in humans, SSTR5-AS1, which encodes a 
long intergenic non-coding RNA, and could regulate SSTR5 expression, as has been shown for other NATs. 
Moreover, there are four CpG islands, named hereafter as CpG1-4, which are susceptible zones of 
methylation, along both genes, which could also regulate their expression. Some of those CpG islands are 
in sites of interest, for they could be important in the control of the expression of these genes. Specifically, 
CpG1 overlaps with the last exon of the NAT and CpG2 falls on the big intron of NAT. CpG3 coincides 
with the first exon of the SSTR5 gene, partially overlapping with its promoter, and with another part of the 
larger intron of the SSTR5-AS1. Besides, CpG4 was the largest region identified and was subdivided into 
three subzones for the purpose of the study: CpG4.1 overlaps with the start of the NAT, possibly with its 
promoter, and the intron of SSTR5; CpG4.2 falls in the exon of SSTR5 and coincides with the coding 
sequence of the canonical SST5; CpG4.3 overlaps with the center of the large exon of SSTR5 gene, 
including its zone of alternative splicing, and the zone immediately previous to the SSTR5-AS1 gene.
In the first experimental assay, we used bisulfite sequencing to measure the methylation levels of these 
four CpG zones (Figure 1B) in a cohort of 11 normal pituitary (NP) samples and 27 samples of 
somatotrope tumors causing acromegaly (summarized in Supplemental Table 1). Specifically, CpG1 was 
20 % more intensely methylated in somatotropinomas than in NP. In contrast, CpG3, which displayed 
levels of less than 5 % of methylation in all the samples, exhibited a marginally lower, but significant, 
degree of methylation in somatotropinoma than in NP samples. In CpG4.1 and CpG4.2, methylation levels 
were between 10 and 20 %, but no significant differences were observed; whereas, in CpG4.3 methylation 
levels showed a significant decrease of approximately 5 % in somatotropinomas compared to NPs, albeit 
displaying very high levels in both cases. Similarly, CpG2 showed high methylation levels, although no 
significant differences were observed between groups.
As a next step, we evaluated the RNA levels of the two genes of interest, SSTR5 and SSTR5-AS1, in 
the same cohorts of somatotropinoma and NP samples (Figure 1C). Interestingly, SSTR5 was clearly 
overexpressed in somatotropinoma samples compared to NP tissues, whereas expression levels of SSTR5-
AS1 gene showed a similar trend but did not exhibit a statistically significant change. Of note, the 
expression of both genes showed a direct correlation in both NP and somatotropinoma samples (Figure 
1D), which could suggest a possible functional association between these two genes. Conversely, no 
correlations were observed between the expression of the antisense gene and the SST5TMD4 truncated 
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Expression of SSTR5 and SSTR5-AS1 genes were next compared with methylation levels of the CpG 
islands overlapping them in the genome. Remarkably, expression of both genes was tightly and inversely 
correlated with methylation levels of CpG4.3 (Figure 1E) in somatotropinoma but not in NP samples, 
whereas they did not show a significant correlation with methylation levels of any of the other CpG islands 
examined (Supplemental Figure 3). CpG4.3 overlaps two functionally relevant regions; the large exon of 
SSTR5 wherein non-canonical alternative splicing can take place, and the putative promoter of SSTR5-AS1. 
Therefore, the methylation at CpG4.3 could be related with the expression of these two genes in 
somatotropinomas, in a manner that might be relevant to their pathological context. Nonetheless, the 
methylation levels of this CpG island or any of the others measured in this work did not exhibit correlations 
with the expression levels of the truncated isoform SST5TMD4 (Supplemental Figure 4).
In order to investigate whether the relationship between SSTR5 and its NAT SSTR5-AS1 is also present 
in other tumors where the somatostatin-SST system is important, we extended our study to PanNETs. To 
this end, expression of both genes was measured in a cohort of 15 PanNETs, comparing tumor tissue with 
their paired non-tumor adjacent tissue (NTAT), used as reference. Results from this analysis revealed that, 
while SSTR5 expression did not differ between both regions, the levels of SSTR5-AS1 mRNA were 
significantly higher in tumor samples (Figure 1F). By contrast, expression levels of these genes were 
directly and strongly associated in both tumor and non-tumor tissue, reinforcing the idea of a functional 
link between them (Figure 1G). Unfortunately, the methylation levels of these samples could not be 
measured due to the limited quality of the DNA from formalin fixed paraffin-embedded samples.
3.2 SSTR5-AS1 and SSTR5 expression levels are interrelated and may be altered by demethylases
To better understand the potential functional role of SSTR5-AS1 in NETs, we performed a stable 
silencing of this NAT using a specific shRNA and interrogated its possible link with the SSTR5 gene. For 
this and the ensuing assays, the PanNET model cell lines BON-1 and QGP-1 were used, also due to the 
lack of suitable human cell models for somatotropinomas. After silencing, cells were treated with 
pasireotide, a second generation SSA with high affinity for SST5, in order to test if SSTR5-AS1 may impact 
in the cell response to this treatment. Interestingly, the first observation was that SSTR5-AS1 silencing by 
30 %, concomitantly decreased SSTR5 expression in BON-1 cells (Figure 2A), and, while not reaching a 
significant difference, it caused a similar trend to decrease in QGP-1 cells. The relation between the 
expression of these two genes seems to be reciprocal, working in both directions, in that silencing of SSTR5 
with a specific siRNA also decreases the expression of SSTR5-AS1 (Supplemental Figure 5). Treatment 
with pasireotide (100 nM; 24 h) increased the expression levels of both SSTR5 and SSTR5-AS1 only in 
BON-1 cells, suggesting the existence of a positive feedback regulatory mechanism linking SST5 activation 
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SSTR5-AS1 fully abrogated the stimulatory effect of pasireotide on the expression of this NAT, the same 
did not occur with SSTR5, rather, pasireotide also tended to elevate SSTR5 expression under NAT 
silencing.
Next, to further study the possible role of methylation in the expression of SSTR5 and SSTR5-AS1 
genes, basal methylation levels of CpG islands of interest were measured in BON-1 and QGP-1 cells. 
Interestingly, both cell lines exhibited similar levels of methylation in all the CpG islands evaluated 
(Figure 2B). In fact, their levels were comparable to those observed for the human samples (Figure 1B), 
except for CpG1, which displayed higher methylation levels in both cell lines than in human samples; these 
findings also indicated that this particular zone was more methylated in somatotropinoma samples than in 
NP. To explore this issue in more detail, cells were treated for 48 h with different doses of the 
demethylating agent 5-azacytidine (Supplemental Figure 6A). The highest effects were observed with 5 
μM 5-azacytidine, which acted oppositely in both genes, decreasing SSTR5-AS1 and increasing SSTR5 
expression levels (Figure 2C). This finding contrasts with the direct correlation of the expression levels of 
both genes observed in the previous measurements and may unveil a potential for a distinct epigenetic 
regulation for each gene. However, despite the ability of 5-azacytidine treatment to clearly influence gene 
expression, no specific alterations were found in the methylation of the CpG islands studied (Supplemental 
Figure 6B). These results may suggest that the changes observed are not a direct consequence of a 
demethylation of SSTR5/SSTR5-AS1 but may reflect off-target effects of the dose of 5-azacytidine used or 
may be mediated by an indirect influence of trans-regulatory elements, such as transcription factors. In any 
case, our findings in the cell lines suggest that DNA methylation may not be a direct regulatory mechanism 
for the expression of SSTR5/SSTR5-AS1 but may influence it indirectly.
3.3 Decrease in SSTR5-AS1 expression promotes aggressiveness features in vitro
To further examine the functional role of SSTR5-AS1, we tested whether the presence of this NAT 
influences tumor aggressiveness features in vitro using the BON-1 and QGP-1 cell models. Specifically, 
proliferation was measured in these cell lines, while colony formation and migration were measured in 
BON-1, under SSTR5-AS1 silencing and pasireotide treatment. This approach first showed that NAT 
silencing clearly increased cell proliferation under basal culture conditions. Conversely, pasireotide did not 
alter proliferation under basal conditions while it seemingly blunted the effect of NAT silencing (Figure 
3A). Interestingly, colony formation was also elevated after SSTR5-AS1 silencing, as compared to its 
scramble control, further suggesting the ability of this NAT to influence malignancy features of NET cells. 
Conversely, pasireotide did not alter colony formation under control conditions, while, again, blunting the 
stimulatory action of NAT silencing (Figure 3B). In contrast with the above, SSTR5-AS1 silencing did not 









Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & 
Sons Ltd.
between the actions of SSTR5-AS1 on these distinct functional cell features. Of note, pasireotide, while, as 
in the previous parameters measured, did not alter migration under control conditions (scramble shRNA), 
surprisingly increased migration when SSTR5-AS1 was silenced (Figure 3D). We were also able to 
evaluate cell proliferation on QGP-1 cells, and we observed that NAT silencing also increased cell 
proliferation under basal conditions (Figure 3F); moreover, after NAT silencing, pasireotide exerted an 
additional stimulatory effect in this cell line, which is reminiscent of the results found in migration studies 
on BON-1 cells. These observations highlight the relevance of the consequences that changes in SSTR5-
AS1 expression may impact on the function of SSTR5 gene; in fact, proliferation assays performed after 
SSTR5 silencing resulted in similar, consistent increases in both cell lines (Supplemental Figure 7).
In line with this, we finally evaluated the impact of SSTR5-AS1 on the activation of key proteins within 
typical signaling pathways regulated by SST5. Thus, activation of AKT and ERK were assessed after 
SSTR5-AS1 silencing and after 10 min of pasireotide treatment. Results obtained showed that NAT 
silencing decreased both AKT and ERK activation, compared to scramble shRNA (Figure 4). Interestingly, 
pasireotide treatment exerted a slight but significant effect decreasing both AKT and ERK phosphorylation 
in BON-1 and QGP-1 under control conditions (scramble shRNA). Furthermore, pasireotide was unable to 
appreciably modify their phosphorylation levels after SSTR5-AS1 silencing.
4. Discussion
There is now ample evidence that the somatostatin system plays a key pathophysiological role in 
various tumors, particularly in NETs, where detection of specific SSTs and use of synthetic SSAs provide 
valuable diagnostic and therapeutic tools [16]. SSAs are currently used to control tumor growth and/or 
hormone secretion in somatotropinomas (and other PitNETs) and in PanNETs, when surgery is not 
amenable [17, 28, 50]. SSAs action in these tumors requires sufficient SSTs expression, particularly SST2, 
the primary target of first-generation SSAs, lanreotide and octreotide [16]. Unfortunately, an appreciable 
proportion of patients are unresponsive to SSAs or develop resistance [16, 29]. However, although it might 
apparently represent a survival disadvantage for the tumor, NETs also express high levels of other SSTs, 
especially SST5, which would enable the use of alternative treatments. Indeed, although first-generation 
SSAs bind SST5 with high affinity, this receptor is a better target for the second-generation SSA pasireotide 
[51]. In fact, this SSA is currently used for the treatment of certain patients in different types of NETs [52, 
53].
The biology of SST5 differs substantially from that of SST2 or the other SSTs, and is still far from 
being fully understood [16, 54]. High SST5/SST2 ratio has been linked to SSAs resistance in acromegaly 
[33, 55, 56]. Likewise, human SSTR5 is the only gene of the SSTR family that, despite lacking typical 
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overexpressed in NETs and have been linked to oncogenic processes and SSAs resistance [16, 25, 33]. This 
underscores the importance of advancing in our understanding of the mechanisms regulating SSTR5 
expression and the biogenesis of SST5, and to identify putative factors controlling its functioning in NETs.
In this scenario, we initially applied an in silico analysis of the SSTR5 gene region that revealed the 
existence of a natural antisense transcript (NAT) overlapping in the genome with SSTR5 gene, which had 
already been named, accordingly, SSTR5-AS1, but whose role or regulation had not yet been reported. A 
closer analysis revealed that, distributed along the loci of these two genes, there are four CpG islands which 
could be targets for DNA methylation. We then analyzed in detail these two original features of SSTR5 in 
NETs. Specifically, presence and relative abundance of SSTR5-AS1 with respect to SSTR5 was examined in 
somatotropinomas and PanNETs, whereas methylation levels of the different islands were measured in two 
PanNET cell lines and in the cohort of somatotropinomas. Results from this latter approach revealed, for 
the first time, that some of these CpG islands were differentially methylated in somatotropinomas, 
compared with normal pituitary (NP). Specifically, the CpG island overlapping the last exon of the NAT 
gene SSTR5-AS1 was more methylated in somatotropinomas than in NP, whereas the one overlapping the 
first exon of SSTR5, and its putative promoter was hypomethylated in somatotropinomas compared to NP. 
The most distant part, overlapping the area where alternative splicing is presumed to occur, in the middle of 
the large exon of SSTR5 and the putative NAT promoter, was significantly less methylated in 
somatotropinomas than in NP. Moreover, methylation levels of CpG4.3 were tightly associated with SSTR5 
and SSTR5-AS1 expression in somatotropinomas, where lower levels of methylation were linked to higher 
expression of these genes, but not in NP samples. These findings suggest that methylation of this CpG 
island could be related to the expression of these two genes in a pathologically relevant context, which is in 
line with results from a recent study that examined SSTR5/SSTR5-AS1 in laryngeal carcinoma [38]. 
However, although the treatment with the demethylating agent 5-azacitydine clearly altered the expression 
of both genes in the cell lines studied, no specific changes were observed in the methylation of the specific 
CpG islands analyzed; therefore, further studies are warranted to test whether these observations also occur 
in primary tumors and to precisely dissect the mechanisms underlying the observed changes, which might 
derive from off-target and/or indirect effects of the demethylating agent, and, in turn, would suggest that 
methylation may not be directly, but indirectly involved in SSTR5/SSTR5-AS1 expression. In particular, the 
lack of association between methylation in CpG4.3 and SSTR5/SSTR5-AS1 expression in NP is intriguing 
and could suggest a differential regulatory role of this interaction in normal somatotropes, or a distinct 
contribution of the heterogeneous cell population comprising healthy pituitary tissue, compared to the 
monoclonal tumor somatotrope population comprising GH-secreting tumors. Nonetheless, the present 
findings provide novel cues to further explore and understand the regulation of SSTR5 expression in tumor 
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There is increasing interest in NATs given their ability to regulate the expression of their sense genes 
[36]. Consequently, we analyzed the expression of SSTR5-AS1 and its relationship with that of SSTR5 on 
the same cohort of somatotropinoma samples as well as in an additional set of PanNETs. Interestingly, 
SSTR5-AS1 expression in PanNETs was higher in tumor tissue as compared to the non-tumor adjacent 
tissue. In contrast, no such differences were found in somatotropinomas compared to NP. However, in both 
PitNETs and PanNETs, as well as in their respective control tissues, we discovered an interesting common 
behavior: there was a tight, direct association between the expression of SSTR5-AS1 and that of SSTR5. 
These results are in agreement with the findings reported in laryngeal carcinoma [38], and support a close 
relationship between the control of both genes, which may involve a regulation by common factors, but 
also a direct interaction of the two genes during their expression. This latter mechanism is likely to be in 
place, in that our results not only proved that silencing of SSTR5-AS1 caused a marked decrease in SSTR5 
expression in vitro, but also silencing of SSTR5 caused a decrease in SSTR5-AS1 in BON-1 and QGP-1 
cells.
We next sought to further understand the precise functional role of SSTR5-AS1 gene in NETs, by 
evaluating different mechanistic endpoints on the PanNET BON-1 and QGP-1 cell models after silencing 
this NAT. This approach revealed that SSTR5-AS1 silencing had a profound functional impact, as it 
increased cell proliferation and/or colony formation in BON-1 and QGP-1 cells. This fact may appear 
somewhat counterintuitive, since this gene is overexpressed in tumoral tissues; however this observation is 
likely linked to the inhibition of SSTR5 expression mentioned above, since this receptor can exert antitumor 
functions and has been shown to have ligand-independent constitutive activity, as it is suggested by the 
results of the proliferation assay after silencing SSTR5 and as it has been reported in the literature [16, 18, 
57]. In contrast, SSTR5-AS1 silencing caused a decrease in cell migration, apparently implying that this 
NAT, either directly or through SST5 could contribute to sustain the migratory capacity of BON-1 cells 
under basal culture conditions. These observations unveil an apparent divergence between two typical 
tumor features, in that a reduction in the expression of this NAT would concomitantly increase proliferation 
but decrease migration. Obviously, it would be of interest to explore whether these actions caused by the 
partial loss of SSTR5-AS1 bear similar consequences in vivo, particularly in tumors. These seemingly 
opposing actions may involve a distinct ability of SSTR5-AS1 to influence downstream signaling, as its 
silencing decreased activation of AKT and ERK, two key players in pathways controlling multiple cell 
functions and with a complex cross-talking regulatory network. Typically, AKT and ERK inhibition are 
related with antitumor actions [58, 59], which would be in keeping with the downregulation of migration 
observed after SSTR5-AS1 silencing. In fact, these pathways have been previously related with SSTR5 in 
the literature [16]. However, these reductions would not similarly fit with the increased proliferation and 
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actions and, therefore, that further studies are necessary to fully elucidate the mechanisms mediating 
SSTR5-AS1 function.
A final set of studies was aimed to ascertain whether SSTR5-AS1 may influence the response of BON-
1 and QGP-1 cells to the SST5-preferring SSA pasireotide. Interestingly, pasireotide treatment increased 
SSTR5 expression in BON-1 cells, similar to that previously reported by our group in pituitary tumor cells 
[43]. But, most importantly, pasireotide also increased SSTR5-AS1 expression, which could imply that the 
positive feedback between SST5 activation and expression of this receptor may involve or, at least be 
related to, that of the NAT itself. This effect was not observed in QGP-1 cells, probably due to the different 
origin of these two cell lines, as underscored by recent studies indicating that these cells are molecularly 
and functionally different [39]. In fact, presence of SSTR5-AS1 shRNA impaired pasireotide to increase 
NAT expression in BON-1 cells but not in QGP-1 cells; this differential action was not only cell type-
dependent but also gene-dependent, as NAT silencing did not seem to fully abrogate the ability of 
pasireotide to upregulate SSTR5 expression in BON-1 cells. Moreover, in keeping with our previous 
findings in PanNET cell lines [22, 60, 61], the functional and signaling actions of pasireotide in these cells 
were limited in terms of cell proliferation and protein activation, as it did not alter most of the parameters 
measured, nor was able to overcome the reduction in AKT and ERK activation caused by SSTR5-AS1 
silencing. Oddly enough, under this silencing pasireotide stimulated cell migration in BON-1 cells, while it 
had no effect in non-silenced control cells. These results are different from those reported on other NET 
cells expressing SSTR5, as it is the case of PitNET cells reported by Peverelli E., et al. [62], where 
pasireotide significantly decreased cell migration of GH3 cell line and human primary PitNET cell cultures. 
These apparent discrepancies may be related to the marked biological differences between PitNET and 
PanNET, in that in BON-1 cells, a typical model from the latter, derived from aggressive cells from a 
lymph node metastasis of a NET, we observed that pasireotide did not have any effect on ERK or AKT 
activation. These results, together with the increased proliferation in response to pasireotide in QGP-1 cells, 
confirm the unexpected but limited ability of pasireotide to influence key functional parameters in 
PanNETs bearing SST5 and, at the same time, unveil an association between SST5 activation, expression of 
SSTR5 and its NAT, SSTR5-AS1, and the actions of pasireotide on key features in cancer cells, 
proliferation, and migration, which warrant further investigations in PanNETs cells.
5. Conclusions
In summary, our study uncovers two novel mechanisms that may be related to the regulation of SSTR5 
expression in cells from PanNETs and somatotropinomas, namely, differential methylation of intragenic 
regions and post-transcriptional events mediated by SSTR5-AS1. The results presented herein reveal that 
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of both SSTR5 and SSTR5-AS1 expression. While SSTR5-AS1 clearly influences SSTR5 and SSTR5-AS1 
expression as well as promotes NET cell aggressiveness features, including proliferation, migration, and 
colony formation, and can be involved in the limited response of PanNET cells to pasireotide. However, the 
precise contribution of these new regulatory mechanisms of SST5 biology to the clinical behavior and 
pharmacological response of pituitary and pancreatic NETs as well as other tumors warrants and awaits 
future elucidation.
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Figure legends
Figure 1. Expression of SSTR5 is regulated by DNA methylation and NAT. A. Cartoon representation 
of SSTR5-AS1 and SSTR5 loci, based on Genome Browser information. B. Comparison of methylation 
levels between somatotropinoma (SOMAT) and normal pituitary (NP) samples, expressed as percentage, 
under t test. C. Expression levels of SSTR5 and SSTR5-AS1 (t test) and (D) correlations (Pearson 
correlation) between them in somatotropinomas and NPs, measured by qPCR and normalized by ACTB. E. 
Correlations (Pearson correlation) between methylation levels of CpG4.3 and expression levels of SSTR5 
and SSTR5-AS1 in somatotropinoma samples. F. Expression levels of SSTR5 and SSTR5-AS1 (Mann-
Whitney U test) and (G) correlations (Spearman correlation) between them in PanNETs and non-tumor 
adjacent tissue (NTAT), measured by qPCR and normalized by RNA18S1. Asterisks (*, p < 0.05; ***, p < 
0.001) indicate values that significantly differ from control. In all cases, data represent median and 
interquartile range of 27 somatotropinomas, 11 NPs and 15 PanNETs with their NTAT.
Figure 2. Interrelation of SSTR5-AS1 and SSTR5 expression and regulation by 5-azacytidine. A. 
Expression levels of SSTR5-AS1 and SSTR5 were evaluated in BON-1 and QGP-1 cell lines after SSTR5-
AS1 silencing (striped bars) and 24 h treatment with pasireotide 100 nM (Pas, blue), and were measured by 
qPCR, and adjusted by normalization factor (NF) with ACTB, GAPDH and HPRT housekeeping genes. B. 
Basal methylation levels of BON-1 and QGP-1 in SSTR5 and SSTR5-AS1 loci, expressed as percentage. C. 
RNA expression of SSTR5-AS1 and SSTR5 after treatment with 5-azacytidine demethylase. Asterisks (**, p 
< 0.01; ***, p < 0.001) indicate values that significantly differ between groups under one-way ANOVA 
analysis; # symbol indicates values that significantly differ from control under t test. In all cases, data 
represent mean ± SEM of n = 3 and 5 independent experiments for BON-1 and QGP-1, respectively.
Figure 3. Alteration of aggressiveness features after SSTR5-AS1 silencing in BON-1 and QGP-1. A. 
Proliferative rate of BON-1 cells after 10 days of silencing (striped bars) and/or pasireotide treatment (Pas, 
blue), represented as area covered in the well. B. Capacity to form colonies under SSTR5-AS1 silencing 
(striped bars) and/or 24 h of pre-treatment with pasireotide (blue), measured by number of colonies after 10 
days of incubation. C. Representative pictures of proliferation (top) and colonies formation (bottom) assays 
in BON-1 cells. D. Migration rate under SSTR5-AS1 silencing (striped bars) and/or pasireotide treatment 
(blue), after 24 h of the wound, represented by healed area. E. Representative pictures of migration assay in 
BON-1, scale bars represent 500 m. F. Proliferative rate of QGP-1 cells after 48 h and 72 h. Asterisks (*, 
p < 0.05; **, p < 0.01; ***, p < 0.001) indicate values that significantly differ between groups under one-
way ANOVA analysis; # symbols indicate values that significantly differ from control under t test. In all 
cases, data are presented as percentage of control and represent mean ± SEM of n = 5 independent 
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Figure 4. Silencing of SSTR5-AS1 alters key SST5-related signaling pathways in BON-1 (A and B) 
and QGP-1 (C and D) cells. Protein phosphorylation of AKT and ERK in both cell lines after SSTR5-AS1 
silencing (striped bars) and after 10 min of pasireotide treatment (Pas, blue). This activation was measured 
by western blot and normalized with total AKT/ERK. Asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.01) 
indicate values that significantly differ between groups (one-way ANOVA analysis); # symbol indicates 
values that significantly differ from control under t test. In all cases, data represent mean ± SEM of n = 4 
independent experiments.
Supporting Information
Supplemental table 1. Summary of clinical parameters of somatotropinoma and PanNETs patients.
Supplemental table 2. Details of primers used for quantitative PCR (a), as well as methylation assays 
(b).
Supplemental Figure 1. UCSC Genome Browser (version GRCh37/hg19) representation of SSTR5-
AS1 and SSTR5 loci.
Supplemental Figure 2. Correlations of SSTR5-AS1 and SST5TMD4 expression in NP and 
somatotropinoma samples, measured by qPCR and normalized by ACTB.
Supplemental Figure 3. Correlations between methylation levels of CpGs and expression levels of 
SSTR5 and SSTR5-AS1 in NP and somatotropinoma samples.
Supplemental Figure 4. Correlations between methylation levels of CpGs and expression levels of 
SST5TMD4 in NP and somatotropinoma samples.
Supplemental Figure 5. RNA expression of SSTR5 and SSTR5-AS1 after SSTR5 silencing compared 
to scramble siRNA (100 %).
Supplemental Figure 6. A. RNA expression of SSTR5 and SSTR5-AS1 after treatment with different 
doses of 5-azacytidine in BON-1 and QGP-1. B. Methylation levels of CpGs in cell lines treated with 5-
azacytidine, compared to non-treated control. Asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001) indicate 
values that significantly differ from control under ANOVA analysis.
Supplemental Figure 7. Proliferation assay after SSTR5 silencing in BON-1 and QGP-1 cell lines, 
performed with Alamar Blue. Asterisks (*, p < 0.05; **, p < 0.01) indicate values that significantly differ 
from control under t test. Data are presented as percentage of control.A
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